CLINICAL_TRIALS
trial_result
· 2021-06-15
Clinical Trial Update: Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects [Phase 2]
Summary
Phase 2 trial update on dose escalation of OPK-88003 in adults with Type 2 Diabetes: results completed and posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: OPKO Health, Inc. | Conditions: Type 2 Diabetes Mellitus | Phase 2 | Status: COMPLETED | Results posted: 2021-06-15